Skip to Content

Posts tagged with "Drug Prices"

  • Cancer

    Avastin For Metastatic Breast Cancer: The Whole Story

    Here’s an excellent roundup of the Avastin story, referenced in an earlier post here. I have to say, I’ve been disappointed in some of the commentary on this issue (which that article goes into as well). Too many people have jumped right to the conclusion that yep, here’s what the new health care plan is… Read More
  • Business and Markets

    Going Hollywood

    A reader at one of the big pharma companies sends along this note: . . .Over my 10 years or so of experience, I have seen a severe decline in risk tolerance at my company, and other large companies as well. When we put a project forward, we are told that either: (a) There are… Read More
  • Business and Markets

    Drug Prices in the US: Not So High After All?

    So, who has the highest prescription drug prices in the industrialized world? Why, the US, of course – everyone knows that. (Our generic prices are among the lowest, but not everyone knows that). And how much more do we pay than those fortunate folks over in Europe? Why, double or more, right? Wrong, apparently. There’s… Read More
  • Cancer

    Ipilimumab (And Progress Against Cancer)

    This time last year, Medarex made all sorts of headlines with their antibody ipilimumab. A press release from the Mayo Clinic made it sound like a miracle cure for prostate cancer; the company’s stock soared, and they were acquired not long afterwards by Bristol-Myers Squibb. I wrote about ipilimumab once, and I still get email… Read More
  • Cancer

    Again, What’s It Worth to You?

    Let’s open up a painful subject here. This is prompted, partly, by the news the other day about Erbulin. The main reason I posted about that compound was because of its chemical complexity and total-synthesis heritage, both of which are unusual. But it’s an oncology drug. As such, it looks like an awful lot of… Read More
  • "Me Too" Drugs

    Pfizer’s Future: Biotech Followups

    The Wall Street Journal has an article detailing some of Pfizer’s plans in the biologics area: stepping in with second-generation versions of current winners from other companies. New versions of Rituxan and Enbrel are in the works, with the improvements mostly coming in how often the drugs need to be given. They’re not alone in… Read More
  • Business and Markets

    Colchicine’s Price Goes Through the Roof

    We all hear about the new drugs that have just been approved, and we all keep track of the drugs that are coming off patent. But what about the really old ones, the drugs that made it to the market long before today’s regulatory framework? There have long been medicines that are generally recognized as… Read More
  • Business and Markets

    In Which You Get to Hear the Phrase “Hatch-Waxman” Again

    There’s a constant running battle in the drug industry between the two kinds of pharmaceutical companies: the ones who discover the drugs first, and the ones who sell the drugs cheaply after the patents have expired. It surprises me still how many people I run into (outside my work) who don’t make that distinction, or… Read More
  • Drug Industry History

    Fall From Grace

    A couple of articles have come together and gotten me to thinking. Back during the summer, long-time medicinal chemist Mark Murcko published a short editorial in Drug Discovery Today comemmerating the Apollo 11 moon landing’s 40th anniversary: “People like me, who are old enough to actually remember the events of July 1969, are instantl… Read More
  • Business and Markets

    Lexapro, Forest Labs, and the Hard Sell

    Forest Labs has done very, very well with Lexapro (escitalopram) over the years. They’re a comparatively small company, and their collaboration with Lundbeck (also a comparatively small company) in the antidepressant field has been the biggest event in their history. Lexapro is the pure enantiomer of the earlier Lundbeck drug Celexa (citalopr… Read More